Dark

Check out our Level2View

CLAS
Class Acceleration Corp.
stock NYSE

Inactive

Dec 29, 2022

10.17USD+0.197%(+0.02)72,515

Pre-market

0.00USD-100.000%(-10.15)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 17, 2022

07:30AM EST Claritas Announces Letter of Intent to Acquire Worldwide Rights to GlobeNewswire Inc

Jan 12, 2022

01:23PM EST Claritas Secures $5 Million Equity Financing Facility with Alumina GlobeNewswire Inc

Jan 4, 2022

07:30AM EST Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Companys plans for developing R-107, the Companys nitric oxide-releasing compound, for multiple clinical indications. GlobeNewswire Inc

Dec 22, 2021

07:15AM EST Claritas Pharmaceuticals, Inc.(TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas")today announcedthat it will develop R-107 for the treatment of persistent pulmonary hypertension of the newborn (PPHN). GlobeNewswire Inc

Dec 21, 2021

07:15AM EST Claritas Completes Acquisition of Exclusive Worldwide Rights to GlobeNewswire Inc

Dec 20, 2021

07:15AM EST Claritas Announces Publication of Peer-Reviewed Article Reporting GlobeNewswire Inc

Nov 30, 2021

04:29PM EST Class Acceleration Corp. Receives NYSE Notice Regarding Delayed Form 10-Q Filing Benzinga

Nov 29, 2021

04:30PM EST Class Acceleration Corp. Receives NYSE Notice Regarding Delayed GlobeNewswire Inc

Nov 18, 2021

07:15AM EST Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today provided an update regarding the expected time to completion of its Phase 1 clinical study of R-107, the Companys proprietary, liquid, nitric oxide-releasing compound (the Phase 1 Study). GlobeNewswire Inc

Nov 4, 2021

07:15AM EDT Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") today announced the engagement of B. Riley Securities, Inc. (B. Riley Securities) as its exclusive capital markets advisor with respect to the Companys planned up-listing of its securities on the OTCQB. GlobeNewswire Inc

Oct 19, 2021

07:15AM EDT Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") is pleased to announce that it has closed the first tranche of a private placement offering (the Offering) of convertible debentures with Obsidian Global GP, LLC (Obsidian) for net proceeds of USD $930,000. GlobeNewswire Inc

Sep 16, 2021

07:15AM EDT Claritas Announces Option to Acquire Rights to Novel Drug for GlobeNewswire Inc

Aug 18, 2021

01:13PM EDT IIROC Trading Resumption - CLAS PR Newswire

12:53PM EDT Claritas Announces Proposed Financing with Obsidian Global GP, GlobeNewswire Inc

11:54AM EDT IIROC Trading Halt - CLAS PR Newswire

Jul 26, 2021

07:15AM EDT Claritas Cites Data from Study Demonstrating Effectiveness of GlobeNewswire Inc

Jul 21, 2021

07:15AM EDT Claritas Announces Additional Data in Validated Animal Model of GlobeNewswire Inc

Jun 10, 2021

07:15AM EDT Claritas Announces Commitments from Companys GlobeNewswire Inc

Jun 3, 2021

05:45PM EDT Class Acceleration Corp. Receives NYSE Notice Regarding Delayed GlobeNewswire Inc

Jun 1, 2021

07:15AM EDT Claritas Announces Transfer of GVHD Program and Cancellation of GlobeNewswire Inc

May 11, 2021

08:30AM EDT Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE (TSXV): CLAS and OTC: KALTF) (the Company or Claritas) today issued the following letter to shareholders from Robert Farrell, the Companys President and CEO. GlobeNewswire Inc

Apr 29, 2021

06:18PM EDT Forbes Considering SPAC Merger: Report Benzinga

Apr 21, 2021

05:00AM EDT Claritas Announces Agreement with CMAX Clinical Research for Phase GlobeNewswire Inc

Apr 14, 2021

01:52PM EDT Claritas Announces Letter of Intent to Acquire Exclusive Worldwide GlobeNewswire Inc

Apr 8, 2021

08:15AM EDT Claritas Pharmaceuticals, Inc.(TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas")today announcedthat, based on significantly positive results in a controlled large animal model of sepsis, the Company will now expand its R-107 development program to include the treatment of COVID-19 related sepsis, the leading cause of death in COVID-19 patients. GlobeNewswire Inc

Share